Roth Capital Predicts Cingulate’s Q1 Earnings (NASDAQ:CING)

Cingulate Inc. (NASDAQ:CING) – Investment analysts at Roth Capital lifted their Q1 2026 earnings per share (EPS) estimates for Cingulate in a research report issued on Thursday, September 18th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings per share of ($0.46) for the quarter, up from their prior forecast of ($0.48). Roth Capital currently has a “Buy” rating on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share.

Separately, Ascendiant Capital Markets increased their target price on Cingulate from $61.00 to $62.00 and gave the stock a “buy” rating in a research report on Friday, August 22nd. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $26.25.

Cingulate Trading Up 0.6%

NASDAQ CING opened at $3.54 on Monday. The business’s 50-day moving average price is $4.38 and its 200 day moving average price is $4.18. Cingulate has a twelve month low of $3.02 and a twelve month high of $6.01. The company has a market capitalization of $19.15 million, a PE ratio of -0.86 and a beta of -0.76.

Cingulate (NASDAQ:CING) last posted its quarterly earnings data on Tuesday, August 19th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.27).

Institutional Investors Weigh In On Cingulate

An institutional investor recently bought a new position in Cingulate stock. XTX Topco Ltd bought a new stake in shares of Cingulate Inc. (NASDAQ:CING) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 10,943 shares of the company’s stock, valued at approximately $45,000. XTX Topco Ltd owned 0.21% of Cingulate as of its most recent filing with the SEC. Institutional investors and hedge funds own 41.31% of the company’s stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.